

Givosiran (Givlaari)

Provider Order Form rev. 07/30/2025



PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Patient Name: _____ DOB: _____ Patient Phone: _____

Patient Address: _____ Patient Email: _____

Allergies: _____ NKDA Weight (lbs/kg): _____ Height (in/cm): _____

Sex: M / F Date of Last Infusion: _____ Next Due Date: _____ Preferred Location: _____

DIAGNOSIS (Please provide ICD-10 code in space provided)

Acute Hepatic Porphyria: _____

Other: _____ Description: _____

THERAPY ADMINISTRATION (Select one)

Administer Givlaari 2.5mg/kg x _____ kg = _____ mg

sub-q every month

Administer Givlaari _____ mg sub-q every month

Monitor for injection site reaction. Monitor patient for 15mins after first injection.

DOSING INFORMATION

Dose reduction to 1.25mg/kg may be needed if patient has a significant change in transaminase levels (AST/ALT).

ADDITIONAL ORDERS

PRE-MEDICATION ORDERS

Other: _____

LABORATORY ORDERS

Other: _____

NURSING

Hold infusion and notify provider for:

- AST or ALT greater than 3 times normal level
- Decreasing renal function

Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

PROVIDER INFORMATION

Preferred Contact Name: _____ Preferred Contact Email: _____

Ordering Provider: _____ Provider NPI: _____

Referring Practice Name: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval)

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, LFTs prior to starting treatment and every month for the first 6 months of treatment.

Required Labs: Blood homocysteine levels, Renal function, hepatic function

Provider Name (print)

Provider Signature

Date

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.

Disclaimer: By signing this form, I authorize Novella Infusion and its affiliates to act as my designated agent in submitting prior authorizations, financial assistance applications, and other clinically required information with respect to this patient and order. This enrollment form shall serve as my signature for prior authorizations and financial assistance programs, as requested.